Astra developed by AstraZeneca has shown strong benefits for women recently diagnosed with ovarian cancer in the recent increase in the research and development-driven growth strategy of the Anglo-Swedish drug manufacturer.
Lynparza's potential as a breakthrough drug for this group appeared as the results of an attempt known as SOLO-1 were unveiled at the European Society for Medical Oncology meeting in Munich on Sunday.
It showed that 60 percent of newly diagnosed women whose disease had a specific mutation, BRCA, were progression-free in three years, compared with about 27 percent who had not received the drug.
Dave Fredrickson, head of the oncology business unit in AstraZeneca, said the results gave "hope this will turn into long-term sustainable survival benefits in ovarian cancer and other areas with very high need".
Lynparza was originally approved in 201[ads1]4 by the US Food and Drug Administration in late BRCA mutant ovarian cancer. Another study, SOLO-2, then examined the effect of a "second line" treatment for ovarian cancer, given when an initial treatment has not worked or stopped working.
Fredrickson said that with the SOLO-1 study it was moving the treatment into an "early setting where there is a curative purpose for both physician and patient and therefore these results are so important."  The SOLO-1 results are the last to point to Lynparza potential; Last year, AstraZeneca and US drug maker Merck agreed to collaborate on developing and commercializing the medicine. Last week, both companies announced that the FDA had given "orphan medicinal product" – a status given to medicines for treating rare diseases – for Lynparza in pancreatic cancer.
However, analysts have suggested that the effect shown in the SOLO-1 study may result in limited commercial returns because the pool of patients with the relevant genetic mutation is a relatively small proportion of the total sufferers.
Andrew Baum, from Citi, said that he expected "only [about] 500 million dollars on-time sales n this indication
. In general, however, he suggested that the market "underestimate" Lynparza's potential for treatment in other areas, "especially in metastatic ovarian and prostate cancer".
He highlighted Citi's forecast of $ 4 billion in revenue from the drug by 2023 "against consensus of $ 1.8 billion".